Strategic Move Enhances Teva’s Presence in Mexico, the Second Largest Market in Latin America and a Major Emerging Market Brings a Portfolio of Differentiated, Patent-Protected, Fixed-Dose Medicine Combinations, Strong Brand […]
Mylan NV on Monday officially took its takeover bid directly to shareholders of Perrigo Co. (PRGO 0.88 %) after the company’s board and management publicly rebuffed previous advances. Mylan is […]
Lannett Company Inc. has agreed to buy UCB SA’s Kremers Urban Pharmaceuticals Inc. for $1.23 billion. The deal, with tax benefits expected to top $100 million, also calls for potential […]
Incyte to pay Hengrui $25 million upfront plus the potential for milestone and royalty payments WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq: INCY) today announced a global license and collaboration agreement […]
NORWALK, Conn. & BURLINGTON, Mass.–(BUSINESS WIRE)–Xerox (NYSE:XRX) and inVentiv Health today announced Xerox’s acquisition of inVentiv Patient Access Solutions (iPAS), an inVentiv Health company. The acquisition will expand Xerox’s pharmacy […]
Talazoparib Is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer; Clinical Activity Observed in Multiple Oncology Opportunities With Potential for Monotherapy or Combination […]
LONDON— GlaxoSmithKline GSK -3.47 % PLC is selling its remaining rights to a drug for use in treating autoimmune diseases, including multiple sclerosis, to Novartis AG NVS -3.07 % for […]
Rival generic-drug makers Mylan NV and Perrigo Co. both chalked up wins this week in their hostile $36 billion takeover fight, which is heading into the homestretch. Mylan in April […]
